trastuzumab rezetecan
jiangsu hengrui pharma
['shr-a1811']
that poster is the ph1 results for shr-a1811. see link below. shr-a1811 is an adc comprised of an anti-her2 monoclonal antibody, a cleavable linker, and a dna topoisomerase inhibitor payload. does that sound familiar? cause it should. 
📊 Current Health Economic Consultant. Ex-Clinical Research Specialist. Tweeting Market Plays and Areas of Interest. Technical Trader 📈 @Healthonomix